| Schedule of operating segments |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the year ended December 31, 2025: | | | | | | | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Adjustments | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | Cost of revenues | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Gross profit | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 6,776,867 | | | 86,768 | | | 6,863,635 | | | 207,105 | | | 415,073 | | | - | | | 7,485,813 | General and administrative | | | - | | | - | | | - | | | - | | | 3,975,961 | | | 383,702 | | | 4,359,663 | Adjusted loss from operations | | | (6,776,867) | | | (86,768) | | | (6,863,635) | | | (207,105) | | | (4,391,034) | | | (383,702) | | | (11,845,476) | Share-based compensation | | | 203,169 | | | 1,679 | | | 204,848 | | | (204,848) | | | 382,735 | | | (382,735) | | | - | Depreciation and amortization | | | 1,935 | | | 322 | | | 2,257 | | | (2,257) | | | 967 | | | (967) | | | - | Loss from operations | | | (6,981,971) | | | (88,769) | | | (7,070,740) | | | - | | | (4,774,736) | | | - | | | (11,845,476) | Other income, net | | | - | | | - | | | - | | | - | | | 258,481 | | | - | | | 258,481 | Net loss before income taxes | | $ | (6,981,971) | | $ | (88,769) | | $ | (7,070,740) | | $ | - | | $ | (4,516,255) | | $ | - | | $ | (11,586,995) |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the year ended December 31, 2024: | | | | | | | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Adjustments | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | 119,371 | | $ | - | | $ | 119,371 | | $ | - | | $ | - | | $ | - | | $ | 119,371 | Cost of revenues | | | (119,371) | | | - | | | (119,371) | | | - | | | - | | | - | | | (119,371) | Gross profit | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 4,233,771 | | | 249,852 | | | 4,483,623 | | | 135,987 | | | 603,979 | | | - | | | 5,223,589 | General and administrative | | | - | | | - | | | - | | | - | | | 4,016,266 | | | 199,642 | | | 4,215,908 | Adjusted loss from operations | | | (4,233,771) | | | (249,852) | | | (4,483,623) | | | (135,987) | | | (4,620,245) | | | (199,642) | | | (9,439,497) | Share-based compensation | | | 127,774 | | | 4,143 | | | 131,917 | | | (131,917) | | | 197,898 | | | (197,898) | | | - | Depreciation and amortization | | | 3,489 | | | 581 | | | 4,070 | | | (4,070) | | | 1,744 | | | (1,744) | | | - | Loss from operations | | | (4,365,034) | | | (254,576) | | | (4,619,610) | | | - | | | (4,819,887) | | | - | | | (9,439,497) | Other (expenses) income, net | | | (22,342) | | | - | | | (22,342) | | | - | | | 786,149 | | | - | | | 763,807 | Net loss before income taxes | | $ | (4,387,376) | | $ | (254,576) | | $ | (4,641,952) | | $ | - | | $ | (4,033,738) | | $ | - | | $ | (8,675,690) |
Reconciliation to Consolidated Loss Before Income Taxes The following table provides a reconciliation of total segment loss to consolidated loss before income taxes: | | | | | | | | | 2025 | | 2024 | Loss from operations - reportable segments | | $ | (7,070,740) | | $ | (4,619,610) | Loss from operations - corporate | | | (4,774,736) | | | (4,819,887) | Interest income, net | | | 270,170 | | | 213,975 | Other income (expense), net | | | (11,689) | | | 549,832 | Net loss before income taxes | | $ | (11,586,995) | | $ | (8,675,690) |
Segment Assets The Company’s total assets by segment as of December 31, 2025, are presented below: | | | | | | | | | | | | | | | | | | Specialized BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Corporate | | Consolidated | Total assets | | $ | 77,872 | | $ | 2,924 | | $ | 80,796 | | $ | 9,154,725 | | $ | 9,235,521 |
The Company’s total assets by segment as of December 31, 2024, are presented below: | | | | | | | | | | | | | | | | | | Specialized BioTherapeutics | | Public Health Solutions | | Total
Segments | | Corporate | | Consolidated | Total assets | | $ | 48,604 | | $ | 2,038 | | $ | 50,642 | | $ | 8,915,841 | | $ | 8,966,483 |
|